Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 10 Feb 2017
At a glance
- Drugs Dinaciclib (Primary) ; Ofatumumab (Primary)
- Indications B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 07 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 4 Mar 2015.
- 23 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.